Literature DB >> 9817601

Characterization of the regulatory regions of the human aromatase (P450arom) gene involved in placenta-specific expression.

A Kamat1, J L Alcorn, C Kunczt, C R Mendelson.   

Abstract

Aromatase P450 (P450arom), a product of the CYP19 gene, catalyzes the conversion of C19-steroids to estrogens. Human P450arom is expressed in placental syncytiotrophoblast, ovarian granulosa cells, and adipose stromal cells by use of tissue-specific promoters that are located 5' of unique untranslated first exons. Mononuclear cytotrophoblasts isolated from midterm human placenta spontaneously fuse in culture to form multinucleated syncytiotrophoblast. These morphological changes are associated with a marked induction of P450arom gene expression. The majority of P450arom transcripts in placental syncytiotrophoblast contain sequences encoded by exon I.1, which lies more than 35 kb upstream of the translation initiation site in exon II. To functionally map genomic sequences required for placenta-specific P450arom expression, fusion genes containing various amounts of DNA flanking the 5'-end of placenta-specific exon I.1 linked to the human GH (hGH) gene, as reporter, were introduced into primary cultures of human trophoblast cells and other cell types. Since the trophoblast cells manifest high levels of aromatase P450 expression, we believe that this provides a physiologically relevant system for characterizing the regulatory regions of this gene. Expression of the fusion genes increased as a function of time in culture in concert with syncytiotrophoblast differentiation and induction of aromatase activity and of P450arom gene expression. P450arom-hGH fusion genes containing 923 and 501 bp of exon I.1 5'-flanking DNA were expressed at comparable levels; these levels were more than 3-fold greater than those of fusion genes containing 2400 bp of exon I.1 5'-flanking DNA, suggesting the presence of an upstream silencer element(s). Expression of these fusion genes was undetectable in cell lines that do not express aromatase or that express aromatase utilizing a nonplacental P450arom promoter. By contrast, P450arom I.1-hGH fusion genes containing 246, 201, or 125 bp of exon I.1 5'-flanking sequence were expressed both in trophoblast cells and in other cell lines. These findings demonstrate that 501 bp of exon I.1 5'-flanking DNA contain response elements required for trophoblast-specific expression of P450arom. These results also suggest the presence of regulatory elements between -501 bp and -246 bp of exon I.1 5'-flanking sequence that bind inhibitory transcription factors expressed in nontrophoblast cells. Deletion and site-directed mutagenesis experiments further suggest that cis-acting elements, including a GC box and two hexameric sequences present within 246 bp of sequence flanking the 5'-end of exon I.1, contribute to the high levels of P450arom promoter activity in primary cultures of placental cells. By competitive and supershift electrophoretic mobility shift assays, it was observed that the ubiquitously expressed transcription factor Sp1 comprises one of the proteins binding to the GC box in the 5'-flanking sequence of P450arom exon I.1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817601     DOI: 10.1210/mend.12.11.0190

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  14 in total

1.  Estrogen-related receptor gamma (ERRgamma) mediates oxygen-dependent induction of aromatase (CYP19) gene expression during human trophoblast differentiation.

Authors:  Premlata Kumar; Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2011-07-14

2.  The c-Myc-regulated microRNA-17~92 (miR-17~92) and miR-106a~363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation.

Authors:  Premlata Kumar; Yanmin Luo; Carmen Tudela; James M Alexander; Carole R Mendelson
Journal:  Mol Cell Biol       Date:  2013-02-25       Impact factor: 4.272

3.  Human Trophoblast Differentiation Is Associated With Profound Gene Regulatory and Epigenetic Changes.

Authors:  Youn-Tae Kwak; Sribalasubashini Muralimanoharan; Aishwarya A Gogate; Carole R Mendelson
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

4.  A 500-bp region, approximately 40 kb upstream of the human CYP19 (aromatase) gene, mediates placenta-specific expression in transgenic mice.

Authors:  A Kamat; K H Graves; M E Smith; J A Richardson; C R Mendelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

5.  Primate-specific miR-515 family members inhibit key genes in human trophoblast differentiation and are upregulated in preeclampsia.

Authors:  Ming Zhang; Sribalasubashini Muralimanoharan; Alison C Wortman; Carole R Mendelson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

6.  Redox-Sensitive Transcription Factor NRF2 Enhances Trophoblast Differentiation via Induction of miR-1246 and Aromatase.

Authors:  Sribalasubashini Muralimanoharan; Youn-Tae Kwak; Carole R Mendelson
Journal:  Endocrinology       Date:  2018-05-01       Impact factor: 4.736

7.  Estrogen receptor alpha (ERalpha) mediates stimulatory effects of estrogen on aromatase (CYP19) gene expression in human placenta.

Authors:  Premlata Kumar; Amrita Kamat; Carole R Mendelson
Journal:  Mol Endocrinol       Date:  2009-03-19

8.  USF1 and USF2 mediate inhibition of human trophoblast differentiation and CYP19 gene expression by Mash-2 and hypoxia.

Authors:  Bing Jiang; Carole R Mendelson
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 9.  Mechanisms in the regulation of aromatase in developing ovary and placenta.

Authors:  Carole R Mendelson; Amrita Kamat
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-21       Impact factor: 4.292

10.  Transforming growth factor-beta inhibits aromatase gene transcription in human trophoblast cells via the Smad2 signaling pathway.

Authors:  Hong Zhou; Guodong Fu; Hui Yu; Chun Peng
Journal:  Reprod Biol Endocrinol       Date:  2009-12-09       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.